score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.V559G	0.8811	858.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0.0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf	0	0.0	0.0	0.0	KIT p.V559G (Missense)	0.0	MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Putatively Actionable		Clinical evidence		Copy Number	CRKL	Amplification				0.0	0.0									Putatively Actionable	Gefitinib	EGFR inhibition	Targeted therapy	CRKL amplification was observed in an EGFR inhibitor resistant tumor after researchers observed that cells from gefitinib-sensitive cell line (HCC827) overexpressing CRKL became resistant to gefitinib relative to controls.	Cheung HW, Du J, Boehm JS, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1(7):608-25.	https://doi.org/10.1158/2159-8290.CD-11-0046						0				CRKL Amplification		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.P632S	0.0844	237.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	137.0	0.1606	0.9926	BRAF p.P632S (Missense)	1.0	MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.R932P	0.3556	90.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0	0.0	0.0	0.0	EGFR p.R932P (Missense)	1.0	MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability	Guideline		Guideline	Somatic Variant	KIT	Missense	p.P573S	0.8629	839.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0.0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf	0	0.0	0.0	0.0	KIT p.P573S (Missense)	0.0	MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat88		
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G636E	0.3526	380.0	8e-06	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14						0	0.0	0.0	0.0	FLT3 p.G636E (Missense)	1.0	MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G818R	0.302	149.0	8e-06	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846						0	7.0	0.2857	0.1371	ALK p.G818R (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.E221K	0.2984	315.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881													0	65.0	0.2923	1.0	MET p.E221K (Missense)	0.0	MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.S699F	0.223	148.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0.0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75	0	0.0	0.0	0.0	POLD1 p.S699F (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P278L	0.4286	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	TP53 p.P278L (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E844K	0.5238	63.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	65.0	0.2615	1.0	SETBP1 p.E844K (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat88		
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Splice Site		0.5	104.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	4.0	0.5	0.066	BARD1  (Splice Site)	0.0	MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S964F	0.1711	187.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	20.0	0.5	0.4678	BRIP1 p.S964F (Missense)	1.0	MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S913Y	0.5929	226.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	0.0	0.0	0.0	BRIP1 p.S913Y (Missense)	1.0	MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.P436S	0.5102	49.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0	0.0	0.0	0.0	TSC2 p.P436S (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.G1122E	0.2923	130.0	8e-06	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	14.0	0.5714	0.6215	BRCA2 p.G1122E (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P385L	0.3109	193.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951													0	411.0	0.3747	1.0	PBRM1 p.P385L (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability	Preclinical			Copy Number	FGFR2	Deletion				0.0	0.0		Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR2 Deletion		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Splice Site	p.P312L	0.1579	76.0	0.0	0.0																Investigate Actionability	0.0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	725.0	0.2193	1.0	PTPN11 p.P312L (Splice Site)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.S1928L	0.2163	245.0	0.0	0.0																Investigate Actionability	0.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	607.0	0.3921	1.0	PRPF8 p.S1928L (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Nonsense	p.Q483*	0.4874	119.0	0.0	0.0																Investigate Actionability	0.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	PRPF8 p.Q483* (Nonsense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.G438S	1.0	2.0	0.0	0.0																Investigate Actionability	0.0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	RUNX1 p.G438S (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Biologically Relevant				Rearrangement	TET2	Fusion	OGDH--TET2			0.0	0.0																					0				OGDH--TET2 Fusion		MEL-IPI_Pat88		
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S1863L	0.1348	89.0	2.5e-05	0.0																					0	0.0	0.0	0.0	MTOR p.S1863L (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Biologically Relevant				Somatic Variant	TACC3	Nonsense	p.Q319*	0.3034	89.0	0.0	0.0																					0	0.0	0.0	0.0	TACC3 p.Q319* (Nonsense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Biologically Relevant				Somatic Variant	PMS2	Nonsense	p.Q402*	0.1157	121.0	0.0	0.0																					0	217.0	0.0922	1.0	PMS2 p.Q402* (Nonsense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Biologically Relevant				Somatic Variant	POT1	Missense	p.D561N	0.4211	76.0	8e-06	0.0																					0	34.0	0.6176	0.9998	POT1 p.D561N (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.A61V	0.3926	135.0	0.0	0.0																					0	0.0	0.0	0.0	FGFR1 p.A61V (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E444K	0.3407	317.0	0.0	0.0																					0	0.0	0.0	0.0	RUNX1T1 p.E444K (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Biologically Relevant				Somatic Variant	ESRP1	Splice Site		0.3333	33.0	0.0	0.0																					0	0.0	0.0	0.0	ESRP1  (Splice Site)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.G476E	0.3433	67.0	0.0	0.0																					0	0.0	0.0	0.0	ESRP1 p.G476E (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E712K	0.3611	72.0	0.0	0.0																					0	0.0	0.0	0.0	FGFR2 p.E712K (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.E602*	0.431	116.0	0.0	0.0																					0	95.0	0.1895	1.0	NF1 p.E602* (Nonsense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Biologically Relevant				Somatic Variant	NF1	Missense	p.L2298P	0.1864	236.0	0.0	0.0																					0	204.0	0.4118	1.0	NF1 p.L2298P (Missense)		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	MEL-IPI_Pat88-Normal-SM-53U4C
Biologically Relevant				Copy Number	KIT	Amplification				0.0	0.0																					0				KIT Amplification		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	
Biologically Relevant				Copy Number	PDGFRA	Amplification				0.0	0.0																					0				PDGFRA Amplification		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	
Biologically Relevant				Copy Number	FIP1L1	Amplification				0.0	0.0																					0				FIP1L1 Amplification		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	
Biologically Relevant				Copy Number	ERG	Deletion				0.0	0.0																					0				ERG Deletion		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	
Biologically Relevant				Copy Number	FLI1	Deletion				0.0	0.0																					0				FLI1 Deletion		MEL-IPI_Pat88	MEL-IPI_Pat88-Tumor-SM-4DK3E	
Biologically Relevant				Microsatellite Stability	Supporting variants		PMS2 p.Q402* (Nonsense), nan, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PMS2 p.Q402* (Nonsense), nan, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat88		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.9																									0				COSMIC Signature (version 2) 7 (90%)		MEL-IPI_Pat88		
